Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-006 Combined With Other Anti-tumor Therapies in Lung Cancer
NCT07241767Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of FH-006 in non-small cell lung cancer (NSCLC), sponsored by Hengrui. Started Nov 2025; status: recruiting.
02
Drugs
FH-006
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07241767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241767.